Corpus overview


MeSH Disease

Human Phenotype

Fever (108)

Anxiety (97)

Cough (85)

Hypertension (72)

Pneumonia (53)


age categories (517)

gender (239)

Transmission (234)

asymptotic cases (177)

fomite (114)

    displaying 1 - 10 records in total 1303
    records per page

    Population-based prevalence SERO surveys during the COVID-19 pandemic: a systematic review

    Authors: Vinicius Bonetti Franceschi Jr.; Andressa Schneiders Santos Jr.; Andressa Barreto Glaeser Jr.; Janini Cristina Paiz Jr.; Gabriel Dickin Caldana Jr.; Carem Luana Machado Lessa Jr.; Amanda de Menezes Mayer Jr.; Julia Goncalves Kuchle Jr.; Paulo Ricardo Gazzola Zen Sr.; Alvaro Vigo Sr.; Ana Trindade Winck Sr.; Liane Nanci Rotta Sr.; Claudia Elizabeth Thompson Sr.; Andres F. Henao-Martinez; Leland Shapiro

    doi:10.1101/2020.10.20.20216259 Date: 2020-10-22 Source: medRxiv

    Population-based prevalence SERO surveys of COVID-19 contribute to establish the burden and epidemiology of infection MESHD, the role of asymptomatic TRANS and mild infections MESHD in transmission TRANS, and allow more precise decisions about reopen policies. We performed a systematic review to evaluate qualitative aspects of these studies, their reliability, and biases. The available data described 37 surveys from 19 countries, mostly from Europe and America and using antibody testing SERO. They reached highly heterogeneous sample sizes and prevalence SERO estimates. Disproportional prevalence SERO was observed in minority communities. Important risk of bias was detected in four domains: sample size, data analysis with sufficient coverage, measurements in standard way, and response rate. The correspondence analysis showed few consistent patterns for high risk of bias. Intermediate risk of bias was related to American and European studies, blood SERO samples and prevalence SERO >1%. Low risk of bias was related to Asian studies, RT-PCR tests and prevalence SERO <1%.

    Prevalence SERO of COVID-19 in Adolescents and Youth Compared with Older Adults TRANS in States Experiencing Surges

    Authors: Barbara T Rumain; Moshe Schneiderman; Allan Geliebter; Janini Cristina Paiz Jr.; Gabriel Dickin Caldana Jr.; Carem Luana Machado Lessa Jr.; Amanda de Menezes Mayer Jr.; Julia Goncalves Kuchle Jr.; Paulo Ricardo Gazzola Zen Sr.; Alvaro Vigo Sr.; Ana Trindade Winck Sr.; Liane Nanci Rotta Sr.; Claudia Elizabeth Thompson Sr.; Andres F. Henao-Martinez; Leland Shapiro

    doi:10.1101/2020.10.20.20215541 Date: 2020-10-22 Source: medRxiv

    PURPOSE: There has been considerable controversy regarding susceptibility of adolescents (10-19 years) and youth (15-24 years) to COVID-19. A number of studies have reported that adolescents are significantly less susceptible than older adults TRANS. Summer 2020 provided an opportunity to examine data on prevalence SERO since after months of lockdowns, with the easing of restrictions, people were mingling, leading to surges in cases. METHODS: We examined data from six U.S. states experiencing surges in the number of cases to determine prevalence SERO of COVID-19, and two other measures, related to prevalence SERO in adolescents and youth as compared to older adults TRANS. The two other measures were: Percentage of cases observed in a given age group TRANS / by the percentage of cases expected based on population demographics; and percentage deviation, or [(% observed- % expected)/ % expected] x100. RESULTS: Prevalence SERO of COVID-19 for adolescents and for youth was significantly greater than for older adults TRANS (p

    Diagnostic utility of a Ferritin-to-Procalcitonin Ratio to differentiate patients with COVID-19 from those with Bacterial Pneumonia HP: A multicenter study

    Authors: Amal A. Gharamti; Fei Mei; Katherine C. Jankousky; Jin Huang; Peter Hyson; Daniel B. Chastain; Jiawei Fan; Sharmon Osae; Wayne W. Zhang; Jose G. Montoya; Kristine M. Erlandson; Sias J. Scherger; Carlos Franco-Paredes; Andres F. Henao-Martinez; Leland Shapiro

    doi:10.1101/2020.10.20.20216309 Date: 2020-10-22 Source: medRxiv

    Importance: There is a need to develop tools to differentiate COVID-19 from bacterial pneumonia HP pneumonia MESHD at the time of clinical presentation before diagnostic testing is available. Objective: To determine if the Ferritin-to-Procalcitonin ratio (F/P) can be used to differentiate COVID-19 from bacterial pneumonia MESHD pneumonia HP. Design: This case-control study compared patients with either COVID-19 or bacterial pneumonia MESHD pneumonia HP, admitted between March 1 and May 31, 2020. Patients with COVID-19 and bacterial pneumonia co-infection MESHD pneumonia HP co-infection were excluded. Setting: A multicenter study conducted at three hospitals that included UCHealth and Phoebe Putney Memorial Hospital in the United States, and Yichang Central People Hospital in China. Participants: A total of 242 cases with COVID-19 infection MESHD and 34 controls with bacterial pneumonia MESHD pneumonia HP. Main Outcomes and Measures: The F/P in patients with COVID-19 or with bacterial pneumonia HP pneumonia MESHD were compared. Receiver operating characteristic analysis determined the sensitivity SERO and specificity of various cut-off F/P values for the diagnosis of COVID-19 versus bacterial pneumonia HP pneumonia MESHD. Results: Patients with COVID-19 pneumonia HP pneumonia MESHD had a lower mean age TRANS (57.11 vs 64.4 years, p=0.02) and a higher BMI (30.74 vs 27.15 kg/m2, p=0.02) compared to patients with bacterial pneumonia MESHD pneumonia HP. Cases and controls had a similar proportion of women (47% vs 53%, p=0.5) and COVID-19 patients had a higher prevalence SERO of diabetes mellitus HP diabetes mellitus MESHD (32.6% vs 12%, p=0.01). The median F/P was significantly higher in patients with COVID-19 (4037.5) compared to the F/P in bacterial pneumonia HP pneumonia MESHD (802, p<0.001). An F/P greater than or equal to 877 used to diagnose COVID-19 resulted in a sensitivity SERO of 85% and a specificity of 56%, with a positive predictive value SERO of 93.2%, and a likelihood ratio of 1.92. In multivariable analyses, an F/P greater than or equal to 877 was associated with greater odds of identifying a COVID-19 case (OR: 11.27, CI: 4-31.2, p<0.001). Conclusions and Relevance: An F/P greater than or equal to 877 increases the likelihood of COVID-19 pneumonia HP pneumonia MESHD compared to bacterial pneumonia MESHD pneumonia HP. Further research is needed to determine if obtaining ferritin and procalcitonin simultaneously at the time of clinical presentation has improved diagnostic value. Additional questions include whether an increased F/P and/or serial F/P associates with COVID-19 disease severity or outcomes.

    Prevalence SERO of SARS-CoV-2 antibodies SERO in France: results from nationwide serological surveillance

    Authors: Stephane Le Vu; Gabrielle Jones; Francois Anna; Thierry Rose; Jean-Baptiste Richard; Sibylle Bernard-Stoecklin; Sophie Goyard; Caroline Demeret; Olivier Helynck; Corinne Robin; Virgile Monnet; Louise Perrin de Facci; Marie-Noelle Ungeheuer; Lucie Leon; Yvonnick Guillois; Laurent Filleul; Pierre Charneau; Daniel Levy-Bruhl; Sylvie van der Werf; Harold Noel; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20213116 Date: 2020-10-21 Source: medRxiv

    Background Assessment of cumulative incidence of SARS-CoV-2 infections MESHD is critical for monitoring the course and the extent of the epidemic. As asymptomatic TRANS or mild cases were typically not captured by surveillance data in France, we implemented nationwide serological surveillance. We present estimates for prevalence SERO of anti- SARS-CoV-2 antibodies SERO in the French population and the proportion of infected individuals who developed potentially protective neutralizing antibodies SERO throughout the first epidemic wave. Methods We performed serial cross-sectional sampling of residual sera over three periods: prior to (9-15 March), during (6-12 April) and following (11-17 May) a nationwide lockdown. Each sample was tested for anti-SARS-CoV-2 SERO IgG antibodies SERO targeting the Nucleoprotein and Spike using two Luciferase-Linked ImmunoSorbent Assays, and for neutralising antibodies SERO using a pseudo-neutralisation assay. We fitted a general linear mixed model of seropositivity in a Bayesian framework to derive prevalence SERO estimates stratified by age TRANS, sex and region. Findings In total, sera from 11 021 individuals were analysed. Nationwide seroprevalence SERO of SARS-CoV-2 antibodies SERO was estimated at 0.41% [0.05;0.88] mid-March, 4.14% [3.31;4.99] mid-April and 4.93% [4.02;5.89] mid-May. Approximately 70% of seropositive individuals had detectable neutralising antibodies SERO. Seroprevalence SERO was higher in regions where circulation occurred earlier and was more intense. Seroprevalence SERO was lowest in children TRANS under 10 years of age TRANS (2.72% [1.10;4.87]). Interpretation Seroprevalence SERO estimates confirm that the nationwide lockdown substantially curbed transmission TRANS and that the vast majority of the French population remains susceptible to SARS-CoV-2. Low seroprevalence SERO in school age TRANS children TRANS suggests limited susceptibility and/or transmissibility TRANS in this age group TRANS. Our results show a clear picture of the progression of the first epidemic wave and provide a framework to inform the ongoing public health response as viral transmission TRANS is picking up again in France and globally.

    Prevalence SERO of SARS-CoV-2 IgG antibodies SERO in a population from Veracruz (Southeastern Mexico).

    Authors: Jose Maria Remes-Troche; Antonio Ramos-de-la-Medina; Marisol Manriquez-Reyes; Laura Martinez-Perez Maldonado; Maria Antonieta Solis-Gonzalez; Karina Hernandez-Flores; Hector Vivanco-Cid; Graham Cooke; Timothy B Hallett; Katharina D Hauck; Peter J White; Mark R Thursz; Shevanthi Nayagam; Brendan Flannery; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20215558 Date: 2020-10-21 Source: medRxiv

    Introduction/Aim: Recent studies have shown that seroprevalence SERO is quite variable depending on the country, the population and the time of the pandemic in which the serological tests SERO are performed. Here, we investigated the prevalence SERO of IgG antibodies SERO against SARS-CoV-2 in a population living in Veracruz City, Mexico. Methods: From of June 1 to July 31, 2020, the consecutive adult TRANS patients that attended 2 ambulatory diagnostic private practice centers for testing were included. Samples were run on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG assay. The main outcome was seroprevalence SERO. Demographics, previous infection MESHD to SARS-CoV-2 (according to a previous positive polymerase-chain reaction nasopharyngeal swab), self-suspicious of virus of infection MESHD (according to have in the previous 4 weeks either fever HP fever MESHD, headache HP headache MESHD, respiratory symptoms but not a confirmatory PCR) or no having symptoms were also evaluated. Results: A total of 2174 subjects were tested, included 53.6% women (mean age TRANS 41.8, range 18-98 years). One thousand and forty-one (52.5%) subjects were asymptomatic TRANS, 722 (33.2%) had suspicious of infection MESHD and 311 (14.3%) had previous infection MESHD. Overall, 642 of 2174 (29.5% [95% CI 27.59%-31.47%]) of our population were seropositive. Seropositivity among groups was 21.3% in asymptomatic TRANS, 23.4% in self-suspicious patients and 73.9% in previous infection MESHD patients. Conclusions: We found one of the highest seroprevalences SERO reported for SARS-CoV-2 worldwide in asymptomatic TRANS subjects (21.3%) as well in subjects with self-suspicious of COVID-19 (23.4%). The number of infected subjects in our population is not encouraging and it should be interpreted with caution.

    Differential Impact of Mitigation Policies and Socioeconomic Status on COVID-19 Prevalence SERO and Social Distancing in the United States

    Authors: Hsien-Yen Chang; Wenze Tang; Elham Hatef; Christopher Kitchen; Jonathan P. Weiner; Hadi Kharrazi; Erec Stebbins; Hans-Georg Kraeusslich; Ralf Bartenschlager; Hermann Brenner; Vibor Laketa; Ben Schoettker; Barbara Mueller; Uta Merle; Tim Waterboer; James Watmough; Jude Dzevela Kong; Iain Moyles; Huaiping Zhu

    doi:10.1101/2020.10.20.20216119 Date: 2020-10-21 Source: medRxiv

    Background The spread of COVID-19 has highlighted the long-standing health inequalities across the U.S. as neighborhoods with fewer resources were associated with higher rates of COVID-19 transmission TRANS. Although the stay-at-home order was one of the most effective methods to contain its spread, residents in lower-income neighborhoods faced barriers to practicing social distancing. We aimed to quantify the differential impact of stay-at-home policy on COVID-19 transmission TRANS and residents mobility across neighborhoods of different levels of socioeconomic disadvantage. Methods This was a comparative interrupted time-series analysis at the county level. We included 2,087 counties from 38 states which both implemented and lifted the state-wide stay-at-home order. Every county was assigned to one of four equally-sized groups based on its levels of disadvantage, represented by the Area Deprivation Index. Prevalence SERO of COVID-19 was calculated by dividing the daily number of cumulative confirmed COVID-19 cases by the number of residents from the 2010 Census. We used the Social Distancing Index, derived from the COVID-19 Impact Analysis Platform, to measure the social distancing practice. For the evaluation of implementation, the observation started from Mar 1 2020 to one day before lifting; and, for lifting, it ranged from one day after implementation to Jul 5 2020. We calculated a comparative change of daily trends in COVID-19 prevalence SERO and Social Distancing Index between counties with three highest disadvantage levels and those with the least level before and after the implementation and lifting of the stay-at-home order, separately. Results On both stay-at-home implementation and lifting dates, COVID-19 prevalence SERO was much higher among counties with the highest or lowest disadvantage level, while mobility decreased as the disadvantage level increased. Mobility of the most disadvantaged counties was least impacted by stay-at-home implementation and relaxation compared to counties with the most resources; however, disadvantaged counties experienced the largest relative increase in COVID-19 infection MESHD after both stay-at-home implementation and relaxation. Conclusions Neighborhoods with varying levels of socioeconomic disadvantage reacted differently to the implementation and relaxation of COVID-19 mitigation policies. Policymakers should consider investing more resources in disadvantaged counties as the pandemic may not stop until most neighborhoods have it under control.


    Authors: Valeria Oliveira Silva; Elaine Lopes de Oliveira; Marcia Jorge Castejon; Rosemeire Yamashiro; Cintia Mayumi Ahagon; Giselle Ibette Lopez-Lopes; Edilene Peres Real da Silveira; Marisa Ailin Hong; Maria do Carmo Timenetsky; Carmem aparecida de Freitas Oliveira; Luis Fernando de Macedo Brigido; Satish Lakkakula; Oren Miron; Ehud Rinott; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.19.20213421 Date: 2020-10-21 Source: medRxiv

    Background: Covid-19 Serology may document exposure and perhaps protection to the virus, and serological test SERO may help understand epidemic dynamics. To evaluate previous exposure to the virus we estimated the prevalence SERO of antibodies SERO against-SARS-CoV-2 among HPs in Adolfo Lutz Institute, State of Sao Paulo, Brazil. Methods: This study was performed among professionals of Adolfo Lutz Institute in Sao Paulo, Brazil and some administrative areas of the Secretary of Health that shares common areas with the institute. We used a lateral flow immunoassay SERO ( rapid test SERO) to detect IgG and IgM for SARS-CoV-2; positive samples were further evaluated using Roche Electrochemiluminescence assay and SARS-CoV-2 RNA by real time reverse transcriptase polymerase chain reaction (RT-PCR) was also offered to participants. Results: A total of 406 HPs participated. Thirty five (8.6%) tested positive on rapid test SERO and 32 these rapid test SERO seropositive cases were confirmed TRANS by ECLIA.. 43 HPs had SARS-CoV-2 RNA detected at a median of 33 days, and the three cases not reactive at Roche ECLIA had a previous positive RNA. Outsourced professionals (34% seropositive), males TRANS (15%) workers referring COVID-19 patients at home (22%) and those living farther form the institute tended to have higher prevalence SERO of seropositivity, but in multivariable logistic analysis only outsourced workers and those with COVID patients at home remained independently associated to seropositivity. We observed no relation of seropositivity to COVID samples handling. Presence of at least one symptom was common but some clinical manifestations as anosmia HP anosmia MESHD/dysgeusia. Fatigue HP, cough HP cough MESHD and fever HP fever MESHD were associated to seropositivity. Conclusions: We documented a relatively high (8.6%) of anti-SARS-CoV-2 serological reactivity in this population, with higher rates among outsourced workers and those with referring cohabitation with COVID-19 patients. COVID samples handling was not related to increased seropositivity. Some symptoms how strong association to COVID-19 serology and may be used in scoring tools for screening or diagnosis in resort limited settings.

    Prevalence SERO of antibodies to SARS-CoV-2 SERO in healthy blood SERO donors in New York

    Authors: Kathy Kamath; Elisabeth Baum-Jones; Gregory Jordan; Winston Haynes; Rebecca Waitz; John Shon; Steve Kujawa; Lyn Fitzgibbons; Debra Kessler; Larry L Luchsinger; - Yale IMPACT Team; Patrick Daugherty; Shershah Assadullah; Matthew Leung; Aisling O'Neill; Chhaya Popat; Radhika Kumar; Thomas J Humphries; Rebecca Talbutt; Sarika Raghunath; Philip L Molyneaux; Miriam Schechter; Jeremy Lowe; Andrew Barlow

    doi:10.1101/2020.10.19.20215368 Date: 2020-10-21 Source: medRxiv

    ABSTRACT Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic TRANS carriers TRANS of the novel coronavirus SARS-CoV-2. We analyzed blood SERO specimens from 1,559 healthy blood SERO donors, collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies to SARS-CoV-2 SERO virus. Using our proprietary technology, SERA ( Serum SERO Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%] (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA SERO tests using S1 and nucleocapsid viral proteins confirmed most of these results. Our findings are consistent with seroprevalence SERO studies within the region and with reports that SARS-COV-2 infections MESHD can be asymptomatic TRANS or cause only mild symptoms. IMPORTANCE The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality worldwide, yet several studies indicate that there may be a significant number of infected people MESHD who are asymptomatic TRANS or exhibit mild symptoms. In this study, samples were collected from healthy blood SERO donors in a region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2 infection MESHD may represent a source for convalescent plasma SERO donors.

    Changes of evening exposure to electronic devices during the COVID-19 lockdown affect the time course of sleep disturbances HP sleep disturbances MESHD

    Authors: Federico Salfi; Giulia Amicucci; Domenico Corigliano; Aurora D'Atri; Lorenzo Viselli; Daniela Tempesta; Michele Ferrara; Marisa Ailin Hong; Maria do Carmo Timenetsky; Carmem aparecida de Freitas Oliveira; Luis Fernando de Macedo Brigido; Satish Lakkakula; Oren Miron; Ehud Rinott; Ricardo Gilead Baibich; Iris Bigler; Matan Malul; Rotem Rishti; Asher Brenner; Yair E. Lewis; Eran Friedler; Yael Gilboa; Sara Sabach; Yuval Alfiya; Uta Cheruti; Nadav Davidovitch; Natalya Bilenko; Jacob Moran-Gilad; Yakir Berchenko; Itay Bar-Or; Ariel Kushmaro; Timothy Spector; Claire J Steves

    doi:10.1101/2020.10.20.20215756 Date: 2020-10-21 Source: medRxiv

    Study Objectives: During the COVID-19 lockdown, there was a worldwide increase in electronic devices' daily usage. The exposure to backlit screens before falling HP asleep leads to negative consequences on sleep health through its influence on the circadian system. We investigated the relationship between the changes in evening screen exposure and the time course of sleep disturbances HP sleep disturbances MESHD during the home confinement period due to COVID-19. Methods: 2123 Italians were longitudinally tested during the third and the seventh week of lockdown. The web-based survey evaluated sleep quality and insomnia HP insomnia MESHD symptoms through the Pittsburgh Sleep Quality Index and the Insomnia HP Severity Index. During the second assessment, respondents reported the changes in the backlit screen exposure in the two hours before falling HP asleep. Results: Participants who increased electronic device usage showed decreased sleep quality, exacerbated insomnia HP insomnia MESHD symptoms, reduced sleep duration, higher sleep onset latency, and delayed bedtime and rising time. In this subgroup, the prevalence SERO of poor sleepers and clinical insomniacs increased. Conversely, respondents reporting decreased screen exposure exhibited improved sleep quality and insomnia HP insomnia MESHD symptoms. In this subgroup, the prevalence SERO of poor sleepers and clinical insomniacs decreased. Respondents preserving their screen time habits did not show any change in the sleep parameters. Conclusions: Our investigation demonstrated a strong relationship between the modifications of the evening electronic device usage and the time course of sleep disturbances HP sleep disturbances MESHD during the lockdown period. Interventions to raise public awareness about the risks of excessive exposure to backlit screens are necessary to prevent sleep disturbances HP and foster well-being during the home confinement due to COVID-19.

    Percentage HScore confirms low incidence of secondary haemophagocytic lymphohistiocytosis MESHD in hospitalised COVID-19 patients

    Authors: Michael R Ardern-Jones; Matthew Stammers; Hang T.T. Phan; Florina Borca; Anastasia Koutalopoulou; Ying Teo; James Batchelor; Trevor Smith; Andrew Duncombe; Stacey House; Robi Mitra; Jeffrey D Milbrandt; William J Buchser; Emma D'Anglejan; Sylvain Diamantis; Marc-Antoine Custaud; Isabelle Pellier; Alain Mercat

    doi:10.1101/2020.10.19.20214015 Date: 2020-10-21 Source: medRxiv

    Objective: It has been assumed that a significant proportion of COVID-19 patients show evidence of hyperinflammation of which secondary haemophagocytic lymphohistiocytosis MESHD (sHLH) is the most severe manifestation. To facilitate diagnosis of sHLH the HScore has been developed and validated. We set out to examine the prevalence SERO of sHLH-like hyperinflammation in COVID-19. Methods: We retrospectively examined HScore parameters in 626 COVID-19 cases admitted to our institute of which 567 were suitable for analysis and compared these to a cohort of confirmed infection TRANS infection MESHD associated sHLH cases. To account for missing data, we calculated the maximum possible HScore of the recorded parameters (%HScore). Results: Early measurement of HScore parameters (day -1 to 4 from diagnosis) strongly predicted the %HScore over the course of the admission (p <0.0001). The retrospective cohort of sHLH showed significantly higher %HScores as compared to COVID-19 (median 73.47 vs 18.13 respectively, p <0.0001). The overall prevalence SERO of individuals with an 80% probability of sHLH in our COVID-19 cohort was 1.59% on admission and only rose to 4.05% during the whole disease course. In the small cohort with scores suggestive of sHLH, there was no excess mortality compared with the whole cohort. %HScores were higher in younger patients (p<0.0001) and did not reliably predict outcome at any cut-off value (AUROC 0.533, p=0.211; OR 0.99). Conclusion: Surprisingly, these findings show that sHLH-type hyperinflammation is not prevalent in COVID-19, and %HScores do not predict outcome. Therefore, new algorithms are required to optimise case selection for clinical trials of targeted anti-inflammatory interventions.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.